Abstract:Tumorogenesis is characterized by the unregulated proliferation of cells, which is the consequence of dysregulated cell division mechanisms. To ensure the rapid multiplication and invasion, tumor tend to create unique tumor microenvironment (TME) benefiting its own progression. As abnormal component in the body, figuring out how to escape from the supervision and attack of immune system is the key of tumor survival. Angiogenesis, which is mainly triggered by the stimulation of vascular endothelial growth factor (VEGF), is one of its solutions. Characterized by hypoxia, most type of tumor cells significantly upregulate VEGF, which stimulates active construction of tumor neovascularization. [1][2][3] However, the newly-formed tumor blood vessels show series of abnormalities, including increased luminal resistance, increased endothelial permeability and limited blood flow caused by defects in structure. [4] The features above are beneficial to the tumor growth and metastasis, as well as immune evasion, inducing resistance to immunotherapy. It was reported that anti-angiogenesis therapy has been seen as a promising strategy to enhance tumor immune response, which contributes to improve immunosuppressive TME and helps with anti-tumor effects by immune system. [5][6][7] The relation between angiogenesis and immune response was revealed in gene and transcriptomic level. Kurmyshkina et al. focused on the difference of transcriptomic landscapes between early-stage invasive cervical carcinoma (CeCa) and cervical intraepithelial neoplastic lesions (CIN). The authors found that innate immune pathways in early-stage CeCa were significantly upregulated in response to the infection of human papillomavirus, compared with CIN as precursor lesions. The tumors with active immune infiltration showed a more differentiated phenotype, while the ones with increased expression of genes associated with angiogenesis were related to exacerbation of de-differentiation and epithelial-to-mesenchymal transition. As reported, anti-angiogenesis therapy was expected to improve immune evasion and enhance immune infiltration. Shafqat et al. summarized previous studies which focused on tumor angiogenesis and coagulation exert suppressive effects on anti-tumor immune response. Both of them mediates the impacts above through specific mechanisms ultimately leading to the reprogramming of TME. Whether the usage of anti-angiogenic therapies to achieve vascular normalization and ACEi/ARBs to achieve stromal normalization targeting angiogenesis, or anticoagulants targeting coagulation, showed similar result of limit tumor progression and transform TME to favor immune response against tumors. Also, they both demonstrated the efficacy of enhance immunotherapy while combining with ICIs, despite the heterogeneity of tumor types still needs to be considered in the conjunction. It is natural to associate angiogenesis with prognosis since its influence on tumor invasion and progression. Li et al. developed an advanced machine learning model to evaluate the prognosis and therapy response of breast cancer based on several genes related to vascular mimicry (VM), the performance of which continuously exceeds that of traditional ones. The tumor group received higher VM scores than the normal group. The high-risk group showed higher level of tumor mutation burden (TMB) and higher mutation rate of tumor suppressor genes, and higher level of immune escape suggesting poor response to immunotherapy at the same time. Meanwhile, the low-risk group appeared more favorable response to immune checkpoint blockage. Eventually, the authors identified several promising chemotherapy drugs to which was VM related genes sensitive.To summarize, the studies above introduce some latest advances in the roles of angiogenesis and immune response in TME of solid tumors, and hopefully contribute to the further explorations of immunotherapy enhancer. We would like to acknowledge the invaluable support of all authors, reviewers and the editor team during the topic preparation process. We are looking forward to significant breakthroughs in the approach of sensitizing immunotherapy through anti-angiogenesis agents to emerge soon.

The crossroad between tumor and endothelial cells

Endothelial cells in tumor microenvironment: insights and perspectives

A Window of Opportunity: Targeting Cancer Endothelium to Enhance Immunotherapy

Contribution to Tumor Angiogenesis From Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy

Endothelial cell Notch signaling programs cancer-associated fibroblasts to promote tumor immune evasion

Exploring the crosstalk between endothelial cells, immune cells, and immune checkpoints in the tumor microenvironment: new insights and therapeutic implications

Cancer Immunotherapy with "Vascular-Immune" Crosstalk as Entry Point: Associated Mechanisms, Therapeutic Drugs and Nano-Delivery Systems

Signaling crosstalk between tumor endothelial cells and immune cells in the microenvironment of solid tumors

Targeting Cellular Components of the Tumor Microenvironment in Solid Malignancies

Editorial: Community series in the role of angiogenesis and immune response in tumor microenvironment of solid tumor, volume III

Crosstalk between angiogenesis and immune regulation in the tumor microenvironment

Targeting endothelial cell anergy to improve CAR T cell therapy for solid tumors

Abstract B049: Interplay between tumor metabolism, vasculature, and T-cell infiltration in anti-tumor immunity

Tumor Microenvironment and Tumor Targeting Therapy

Aberrant tumor vasculature. Facts and pitfalls

Tumor Immune Evasion Induced by Dysregulation of Erythroid Progenitor Cells Development

Subverting Attachment to Prevent Attacking: Alteration of Effector Immune Cell Migration and Adhesion as a Key Mechanism of Tumor Immune Evasion

Different subpopulations of macrophages, neutrophils, mast cells, and fibroblasts are involved in the control of tumor angiogenesis

Targeting VEGF/VEGFR to Modulate Antitumor Immunity

Tumor-induced neurogenesis and immune evasion as targets of innovative anti-cancer therapies

Towards Targeting Endothelial Rap1B to Overcome Vascular Immunosuppression in Cancer